BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 6, 2006
View Archived Issues
Preclinical and clinical investigation of SNS-595 in cancer advances
Read More
Ambit Biosciences presents new FLT-3 inhibitor for AML
Read More
Wyeth presents novel class of selective cPLA2alpha inhibitors for inflammation
Read More
IND cleared for phase I study of D93
Read More
Orphan drug designation for EPI-A0001
Read More
Epix and Predix sign merger agreement
Read More
Geron studies GRN-163L in patients with solid tumor malignancies
Read More
Phase III breast cancer trial of Tykerb with capecitabine exceeds primary endpoint
Read More
Novel 5-HT6 antagonists from Korean Research Institute of Chemical Technology
Read More
New orally active progesterone receptor agonists presented by Wyeth
Read More
U.S. subsidiaries form new Daiichi Sankyo
Read More
Astellas to acquire worldwide rights to Amevive
Read More
FDA completes IND review for Oncaspar in NHL and solid tumors
Read More
Trials of CX-717 placed on clinical hold
Read More
Incyte discontinues development of DFC
Read More
Initial preclinical data for ReN-003 retinal stem cell therapy program
Read More
Dainippon Sumitomo merges U.S. subsidiaries
Read More
Orphan drug designation for lestaurtinib in AML
Read More
Veronate fails to meet phase III study endpoints
Read More
Celebrex reduces precancerous polyps in high-risk patients
Read More
PTC-124 shows pharmacological activity in CF patients with nonsense mutation
Read More
Novel antiinfective agents reported in recent patent literature
Read More
Novel p38alpha MAPK inhibitors emerge from Pfizer R&D
Read More
Novel agents for respiratory disorders disclosed in recent patents
Read More
Taclonex now available in U.S.
Read More
Pyridopyridazines with potent and selective dual PI3-kinase/ERK2-inhibitory activity
Read More
Second approvable letter for Surfaxin
Read More
Antitumor activity of RGB-286638, a potent, broad-spectrum CDK inhibitor
Read More
Oncogenic B-Raf inhibitor advanced as first oncology candidate at Plexxikon
Read More
Antitumor activity of potent multiple-kinase inhibitor further characterized
Read More
Novel inhibitors of hepatitis C virus replicon system identified
Read More